Skip to main content
SpringerLink
Log in

Anti-IL6-Antikörper punktet bei M. Castleman

  • Literatur kompakt_Leukämien und Lymphome
  • Published:
Im Focus Onkologie Aims and scope

Die multizentrische Form des Morbus Castleman ist eine seltene lymphoproliferative Erkrankung, die durch dysregulierte Interleukin (IL)-6-Produktion entsteht. In einer randomisierten Studie wurde nun ein IL-6-Antikörper getestet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  • Van Rhee F et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014; 15(9):966-74.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Judith Neumaier

Authors
  1. Judith Neumaier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumaier, J. Anti-IL6-Antikörper punktet bei M. Castleman. Im Focus Onkologie 17, 22 (2014). https://doi.org/10.1007/s15015-014-1484-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1484-4

Search

Navigation